"Esterified estrogens" from_date:2012

Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women. Testosterone supplementation is being prescribed increasingly to treat symptoms of hormone deficiency in pre- and postmenopausal women; however, studies of the association of testosterone therapy, alone or in combination with estrogen, with risk of breast cancer are limited. The current study assessed the association of combination conjugated esterified estrogen and methyltestosterone (CEE+MT) use and breast cancer risk in postmenopausal women in the Women's Health Initiative (WHI). At Year 3 of follow-up, women in the WHI observational study (N=71,964) provided information on CEE+MT use in the past two years, duration of use, and the brand name of the product

mg every 3-4 weeks) 4. Estradiol valerate (2-20 mg every other week) 5. Estropipate (1.25-2.5 mg/day) 6. Conjugated Estrogen (e.g. Premarin, Enjuvia) 1. Oral (0.3-1.25 mg/day) 2. Injectable (0.2-2 mg/day) 3. Transdermal 7. Diethylstilbestrol (0.1-0.5 mg/day) 8. Quinestrol (0.1-0.2 mg/week) 9. Chlorotrianisene (12-25 mg/day) 10. Methallenestril (3-9 mg/day) 11. Esterified Estrogen (Menest): 0.3 to 1.25 mg/day VII. Preparations: Native Estrogen with Selective Actions in Tissues (NEST) 1. Background 1. Native Estrogen with Selective Actions in Tissues (NEST) are plant-derived Estrogens (Phytoestrogens) 2. Low potency and therefore 1000-fold higher doses are required (measured in mg NOT mcg) 1. Nextstellis contains 14.2 mg of Estetrol, while most OCPs contain 20-30 mcg

, Enjuvia) 0.625 mg orally daily (or 0.3, 0.45, 0.9, 1.25 mg) 3. Estropipate (Ogen) 0.625 mg orally daily 4. Esterified Estrogen (Estratab, Menest) 0.625 mg orally daily (or 0.3, 1.25, 2.5 mg) 5. Estradiol (Estrace) 0.5 mg orally daily (or 1.0 or 2.0 mg) 6. Estradiol transdermal patch (Estraderm, Alora, Climara, Minivelle) 0.05 mg patch/wk (or 0.025, 0.075 or 0.1) 7. Estradiol transdermal gel (Divigel

. Estropipate (Ogen) 0.625 mg orally daily 4. Esterified Estrogen (Estratab, Menest) 0.625 mg orally daily (or 0.3, 1.25, 2.5 mg) 5. Estradiol (Estrace) 0.5 mg orally daily (or 1.0 or 2.0 mg) 6. Transdermal Estrogen (must be an Estrogen only product if used sequentially) 1. Estradiol transdermal (Estraderm, Alora, Climara, Minivelle) 0.05 mg patch/wk (or 0.025, 0.075 or 0.1) VI. Preparations

-7 [PubMed] 3. NIH Women's Initiative 1. Hazard Ratio for Pulmonary Embolism: 2.13 2. (2002) JAMA 288:321-333 [PubMed] 4. Risk if prior Venous thrombosis occurred 1. Trauma-related: no increased risk 2. Oral Contraceptive related: possible increased risk 5. Esterified Estrogen (Menest) not assoc. with thrombus 1. May

database, further classified as conjugated estrogens, esterified estrogens, and progestin. Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.0-9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6-1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1-22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6-5.0). The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important

mg every 3-4 weeks) 4. Estradiol valerate (2-20 mg every other week) 5. Estropipate (1.25-2.5 mg/day) 6. Conjugated Estrogen (e.g. Premarin, Enjuvia) 1. Oral (0.3-1.25 mg/day) 2. Injectable (0.2-2 mg/day) 3. Transdermal 7. Diethylstilbestrol (0.1-0.5 mg/day) 8. Quinestrol (0.1-0.2 mg/week) 9. Chlorotrianisene (12-25 mg/day) 10. Methallenestril (3-9 mg/day) 11. Esterified Estrogen (Menest): 0.3 to 1.25 mg/day VII. Preparations: Native Estrogen with Selective Actions in Tissues (NEST) 1. Background 1. Native Estrogen with Selective Actions in Tissues (NEST) are plant-derived Estrogens (Phytoestrogens) 2. Low potency and therefore 1000-fold higher doses are required (measured in mg NOT mcg) 1. Nextstellis contains 14.2 mg of Estetrol, while most OCPs contain 20-30 mcg

, Enjuvia) 0.625 mg orally daily (or 0.3, 0.45, 0.9, 1.25 mg) 3. Estropipate (Ogen) 0.625 mg orally daily 4. Esterified Estrogen (Estratab, Menest) 0.625 mg orally daily (or 0.3, 1.25, 2.5 mg) 5. Estradiol (Estrace) 0.5 mg orally daily (or 1.0 or 2.0 mg) 6. Estradiol transdermal patch (Estraderm, Alora, Climara, Minivelle) 0.05 mg patch/wk (or 0.025, 0.075 or 0.1) 7. Estradiol transdermal gel (Divigel

. Estropipate (Ogen) 0.625 mg orally daily 4. Esterified Estrogen (Estratab, Menest) 0.625 mg orally daily (or 0.3, 1.25, 2.5 mg) 5. Estradiol (Estrace) 0.5 mg orally daily (or 1.0 or 2.0 mg) 6. Transdermal Estrogen (must be an Estrogen only product if used sequentially) 1. Estradiol transdermal (Estraderm, Alora, Climara, Minivelle) 0.05 mg patch/wk (or 0.025, 0.075 or 0.1) VI. Preparations

-7 [PubMed] 3. NIH Women's Initiative 1. Hazard Ratio for Pulmonary Embolism: 2.13 2. (2002) JAMA 288:321-333 [PubMed] 4. Risk if prior Venous thrombosis occurred 1. Trauma-related: no increased risk 2. Oral Contraceptive related: possible increased risk 5. Esterified Estrogen (Menest) not assoc. with thrombus 1. May